Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 66.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,283 shares of the biotechnology company's stock after selling 126,974 shares during the quarter. Two Sigma Investments LP owned approximately 0.30% of Enanta Pharmaceuticals worth $370,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ENTA. AlphaQuest LLC grew its position in Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 3,137 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in Enanta Pharmaceuticals by 51.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company's stock valued at $1,668,000 after acquiring an additional 98,285 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $254,000. Millennium Management LLC increased its holdings in Enanta Pharmaceuticals by 22.7% during the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock worth $5,158,000 after buying an additional 165,692 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Enanta Pharmaceuticals by 9.3% during the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after buying an additional 79,197 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ENTA shares. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. JMP Securities upped their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a research report on Tuesday, June 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $18.00.

Enanta Pharmaceuticals Trading Up 1.2%

Enanta Pharmaceuticals stock traded up $0.09 during mid-day trading on Friday, hitting $7.50. The company had a trading volume of 243,932 shares, compared to its average volume of 286,451. The company has a market capitalization of $160.33 million, a PE ratio of -1.52 and a beta of 0.76. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24. The stock's 50 day moving average price is $5.80 and its two-hundred day moving average price is $6.15.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The company had revenue of $14.93 million for the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.